Posts By: biotech

In July 2016 BMC supported OncoArendi Therapeutics in grant application for the project “Development of a first-in-class small molecule drug candidate for cancer treatment through YKL 40 inhibition” in the 1/1.1.1/2016 (“Fast track”) program by The National Centre for Research and Development. The project included substantive preparation of the grant application parts, concerning: – market… Read more »

In Autumn 2015 BMC supported Helix Polska in grant application for 1/1.1.1/2015 (“Fast track”) program by The National Centre for Research and Development, for the project “Development of a new, effective and highly specific therapy for breast cancer, with low toxicity profile, based on patented DOS47 technology platform, modifying tumor’s microenvironment and antitumor immune response… Read more »

In May and July 2015 BMC supported OncoArendi Therapeutics in grant applications for 1/1.1.1/2015 (“Fast track”) program by The National Centre for Research and Development. Commission included description of the market and the profitability of the project implementation in the application concerning “Preclinical research and clinical trials of a first-in-class development candidate in therapy of… Read more »

In June 2015, BMC signed a contract with Jagiellonian Center of Innovation concerning internships for students / PhD students or academic staff of the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University (UJ), under the KNOW program. Due to this cooperation BMC has hosted a doctoral student at the Jagiellonian University, for 2 months. She… Read more »

In January 2014, BMC team performed commercialization potential (QUICK LOOK) analysis of technology developed by dr Jakub Włodarczyk group (Nencki Institute of Experimental Biology Polish Academy of Sciences). Results were presented at the seminar for scientists and Institute’s administration representatives. As a result of a subsequent brain storm, it was decided to seek further support… Read more »

BMC, acting as an external expert, valued R&D programmes of the OncoArendi Therapeutics in the process of valuation of the company for tranactional purposes.  OncoArendi Therapeutics closed on 15th January 2015 a Series A financing round with Michał Sołowow as a leading investor acting via the IPOPEMA 112 FIZAN fund. OncoArendi is a dynamically growing biotechnological… Read more »

BMC and PANWIM Technologie Sp. zo.o.-  a special purpose company founded by the Institute of Fundamental Technological Research, Polish Academy of Sciences and the Military Institute of Medicine- are pleased to announce formation of a partnership in the area of technology transfer and commercialization of research and development projects. PANWIM Technolgie was created as a… Read more »

In September 2014 BMC conducted a detailed market and technology analysis (a kind of an “IN DEPTH” type of analysis) for a one of the OncoArendi Therapeutics’ technologies. Results of the work constituted a basis for the market part of the STRATEGMED application in the National Research and Development competition. The application was positively evaluated… Read more »